Amber Salzman | President and Chief Executive Officer
Adverum Biotechnologies

Amber Salzman, President and Chief Executive Officer, Adverum Biotechnologies

Dr. Salzman was appointed President and Chief Executive Officer of Adverum in October 2016 after joining the company earlier in the year as President and Chief Operating Officer after the merger of Annapurna Therapeutics with Avalanche Biotechnologies. She served as Co-Founder, President and Chief Executive Officer of Annapurna Therapeutics prior to the merger. Previously, Amber successfully served in leadership roles in large pharmaceutical companies, small pharmaceutical companies, and in the rare disease community including her role as Chief Executive Officer of Cardiokine Inc. prior to its acquisition by Cornerstone Therapeutics, Inc. Prior to these roles, she served as a member of the GlaxoSmtihKline plc’s R&D executive team where she planned and managed drug-development projects and clinical trials comprising more than 30,000 patients worldwide. She has led initiatives to accelerate drug development and moderate costs, and established a Development Support Center in India. She is the President of the Stop ALD Foundation, a patient-advocacy group driving forward improvements in treatments for patients with adrenoleukodystrophy (ALD), and she played a key role in bringing about the a ALD lentiviral gene therapy treatment. Dr. Salzman received her B.A. from Temple University and her Ph.D. from Bryn Mawr College.

back to speakers